Pulmonary Arterial Hypertension Treatment Market By Drug Type, By Type, By Route of Administration: Global Opportunity Analysis and Industry Forecast, 2021-2031

Table of Contents

CHAPTER 1: INTRODUCTION
1.1. Report description
1.2. Key market segments
1.3. Key benefits to the stakeholders
1.4. Research Methodology
1.4.1. Secondary research
1.4.2. Primary research
1.4.3. Analyst tools and models

CHAPTER 2: EXECUTIVE SUMMARY
2.1. Key findings of the study
2.2. CXO Perspective

CHAPTER 3: MARKET OVERVIEW
3.1. Market definition and scope
3.2. Key findings
3.2.1. Top investment pockets
3.3. Porter’s five forces analysis
3.4. Top player positioning
3.5. Market dynamics
3.5.1. Drivers
3.5.2. Restraints
3.5.3. Opportunities
3.6. COVID-19 Impact Analysis on the market

CHAPTER 4: PULMONARY ARTERIAL HYPERTENSION TREATMENT MARKET, BY BY DRUG TYPE
4.1 Overview
4.1.1 Market size and forecast
4.2 Endothelin Receptor Antagonists (ERAs)
4.2.1 Key market trends, growth factors and opportunities
4.2.2 Market size and forecast, by region
4.2.3 Market analysis by country
4.3 PDE-5 Inhibitors
4.3.1 Key market trends, growth factors and opportunities
4.3.2 Market size and forecast, by region
4.3.3 Market analysis by country
4.4 Prostacyclin and Prostacyclin Analogs
4.4.1 Key market trends, growth factors and opportunities
4.4.2 Market size and forecast, by region
4.4.3 Market analysis by country
4.5 SGC Stimulators
4.5.1 Key market trends, growth factors and opportunities
4.5.2 Market size and forecast, by region
4.5.3 Market analysis by country

CHAPTER 5: PULMONARY ARTERIAL HYPERTENSION TREATMENT MARKET, BY TYPE
5.1 Overview
5.1.1 Market size and forecast
5.2 Branded
5.2.1 Key market trends, growth factors and opportunities
5.2.2 Market size and forecast, by region
5.2.3 Market analysis by country
5.2.4 Branded Pulmonary Arterial Hypertension Treatment Market by Distribution Channel
5.2.4.1 Retail Pharmacy Market size and forecast, by region
5.2.4.2 Hospital Pharmacy Market size and forecast, by region
5.2.4.3 Online Pharmacy Market size and forecast, by region
5.3 Generics
5.3.1 Key market trends, growth factors and opportunities
5.3.2 Market size and forecast, by region
5.3.3 Market analysis by country
5.3.4 Generics Pulmonary Arterial Hypertension Treatment Market by Distribution Channel
5.3.4.1 Retail Pharmacy Market size and forecast, by region
5.3.4.2 Hospital Pharmacy Market size and forecast, by region
5.3.4.3 Online Pharmacy Market size and forecast, by region

CHAPTER 6: PULMONARY ARTERIAL HYPERTENSION TREATMENT MARKET, BY ROUTE OF ADMINISTRATION
6.1 Overview
6.1.1 Market size and forecast
6.2 Oral
6.2.1 Key market trends, growth factors and opportunities
6.2.2 Market size and forecast, by region
6.2.3 Market analysis by country
6.3 Intravenous/ subcutaneous
6.3.1 Key market trends, growth factors and opportunities
6.3.2 Market size and forecast, by region
6.3.3 Market analysis by country
6.4 Inhalational
6.4.1 Key market trends, growth factors and opportunities
6.4.2 Market size and forecast, by region
6.4.3 Market analysis by country

CHAPTER 7: PULMONARY ARTERIAL HYPERTENSION TREATMENT MARKET, BY REGION
7.1 Overview
7.1.1 Market size and forecast
7.2 North America
7.2.1 Key trends and opportunities
7.2.2 North America Market size and forecast, by by Drug Type
7.2.3 North America Market size and forecast, by Type
7.2.3.1 North America Branded Pulmonary Arterial Hypertension Treatment Market by Distribution Channel
7.2.3.2 North America Generics Pulmonary Arterial Hypertension Treatment Market by Distribution Channel
7.2.4 North America Market size and forecast, by Route of Administration
7.2.5 North America Market size and forecast, by country
7.2.5.1 U. S.
7.2.5.1.1 Market size and forecast, by by Drug Type
7.2.5.1.2 Market size and forecast, by Type
7.2.5.1.3 Market size and forecast, by Route of Administration
7.2.5.2 Canada
7.2.5.2.1 Market size and forecast, by by Drug Type
7.2.5.2.2 Market size and forecast, by Type
7.2.5.2.3 Market size and forecast, by Route of Administration
7.2.5.3 Mexico
7.2.5.3.1 Market size and forecast, by by Drug Type
7.2.5.3.2 Market size and forecast, by Type
7.2.5.3.3 Market size and forecast, by Route of Administration
7.3 Europe
7.3.1 Key trends and opportunities
7.3.2 Europe Market size and forecast, by by Drug Type
7.3.3 Europe Market size and forecast, by Type
7.3.3.1 Europe Branded Pulmonary Arterial Hypertension Treatment Market by Distribution Channel
7.3.3.2 Europe Generics Pulmonary Arterial Hypertension Treatment Market by Distribution Channel
7.3.4 Europe Market size and forecast, by Route of Administration
7.3.5 Europe Market size and forecast, by country
7.3.5.1 Germany
7.3.5.1.1 Market size and forecast, by by Drug Type
7.3.5.1.2 Market size and forecast, by Type
7.3.5.1.3 Market size and forecast, by Route of Administration
7.3.5.2 France
7.3.5.2.1 Market size and forecast, by by Drug Type
7.3.5.2.2 Market size and forecast, by Type
7.3.5.2.3 Market size and forecast, by Route of Administration
7.3.5.3 UK
7.3.5.3.1 Market size and forecast, by by Drug Type
7.3.5.3.2 Market size and forecast, by Type
7.3.5.3.3 Market size and forecast, by Route of Administration
7.3.5.4 Italy
7.3.5.4.1 Market size and forecast, by by Drug Type
7.3.5.4.2 Market size and forecast, by Type
7.3.5.4.3 Market size and forecast, by Route of Administration
7.3.5.5 Spain
7.3.5.5.1 Market size and forecast, by by Drug Type
7.3.5.5.2 Market size and forecast, by Type
7.3.5.5.3 Market size and forecast, by Route of Administration
7.3.5.6 Rest of Europe
7.3.5.6.1 Market size and forecast, by by Drug Type
7.3.5.6.2 Market size and forecast, by Type
7.3.5.6.3 Market size and forecast, by Route of Administration
7.4 Asia-Pacific
7.4.1 Key trends and opportunities
7.4.2 Asia-Pacific Market size and forecast, by by Drug Type
7.4.3 Asia-Pacific Market size and forecast, by Type
7.4.3.1 Asia-Pacific Branded Pulmonary Arterial Hypertension Treatment Market by Distribution Channel
7.4.3.2 Asia-Pacific Generics Pulmonary Arterial Hypertension Treatment Market by Distribution Channel
7.4.4 Asia-Pacific Market size and forecast, by Route of Administration
7.4.5 Asia-Pacific Market size and forecast, by country
7.4.5.1 China
7.4.5.1.1 Market size and forecast, by by Drug Type
7.4.5.1.2 Market size and forecast, by Type
7.4.5.1.3 Market size and forecast, by Route of Administration
7.4.5.2 Japan
7.4.5.2.1 Market size and forecast, by by Drug Type
7.4.5.2.2 Market size and forecast, by Type
7.4.5.2.3 Market size and forecast, by Route of Administration
7.4.5.3 India
7.4.5.3.1 Market size and forecast, by by Drug Type
7.4.5.3.2 Market size and forecast, by Type
7.4.5.3.3 Market size and forecast, by Route of Administration
7.4.5.4 Australia
7.4.5.4.1 Market size and forecast, by by Drug Type
7.4.5.4.2 Market size and forecast, by Type
7.4.5.4.3 Market size and forecast, by Route of Administration
7.4.5.5 South Korea
7.4.5.5.1 Market size and forecast, by by Drug Type
7.4.5.5.2 Market size and forecast, by Type
7.4.5.5.3 Market size and forecast, by Route of Administration
7.4.5.6 Rest of Asia-Pacific
7.4.5.6.1 Market size and forecast, by by Drug Type
7.4.5.6.2 Market size and forecast, by Type
7.4.5.6.3 Market size and forecast, by Route of Administration
7.5 LAMEA
7.5.1 Key trends and opportunities
7.5.2 LAMEA Market size and forecast, by by Drug Type
7.5.3 LAMEA Market size and forecast, by Type
7.5.3.1 LAMEA Branded Pulmonary Arterial Hypertension Treatment Market by Distribution Channel
7.5.3.2 LAMEA Generics Pulmonary Arterial Hypertension Treatment Market by Distribution Channel
7.5.4 LAMEA Market size and forecast, by Route of Administration
7.5.5 LAMEA Market size and forecast, by country
7.5.5.1 Brazil
7.5.5.1.1 Market size and forecast, by by Drug Type
7.5.5.1.2 Market size and forecast, by Type
7.5.5.1.3 Market size and forecast, by Route of Administration
7.5.5.2 Saudi Arabia
7.5.5.2.1 Market size and forecast, by by Drug Type
7.5.5.2.2 Market size and forecast, by Type
7.5.5.2.3 Market size and forecast, by Route of Administration
7.5.5.3 South Africa
7.5.5.3.1 Market size and forecast, by by Drug Type
7.5.5.3.2 Market size and forecast, by Type
7.5.5.3.3 Market size and forecast, by Route of Administration
7.5.5.4 Rest of LAMEA
7.5.5.4.1 Market size and forecast, by by Drug Type
7.5.5.4.2 Market size and forecast, by Type
7.5.5.4.3 Market size and forecast, by Route of Administration

CHAPTER 8: COMPANY LANDSCAPE
8.1. Introduction
8.2. Top winning strategies
8.3. Product Mapping of Top 10 Player
8.4. Competitive Dashboard
8.5. Competitive Heatmap
8.6. Key developments

CHAPTER 9: COMPANY PROFILES
9.1 United Therapeutics Corporation
9.1.1 Company overview
9.1.2 Company snapshot
9.1.3 Operating business segments
9.1.4 Product portfolio
9.1.5 Business performance
9.1.6 Key strategic moves and developments
9.2 Bayer AG
9.2.1 Company overview
9.2.2 Company snapshot
9.2.3 Operating business segments
9.2.4 Product portfolio
9.2.5 Business performance
9.2.6 Key strategic moves and developments
9.3 Gilead Sciences, Inc.
9.3.1 Company overview
9.3.2 Company snapshot
9.3.3 Operating business segments
9.3.4 Product portfolio
9.3.5 Business performance
9.3.6 Key strategic moves and developments
9.4 Johnson & Johnson
9.4.1 Company overview
9.4.2 Company snapshot
9.4.3 Operating business segments
9.4.4 Product portfolio
9.4.5 Business performance
9.4.6 Key strategic moves and developments
9.5 Viatris Inc.
9.5.1 Company overview
9.5.2 Company snapshot
9.5.3 Operating business segments
9.5.4 Product portfolio
9.5.5 Business performance
9.5.6 Key strategic moves and developments
9.6 GlaxoSmithKline
9.6.1 Company overview
9.6.2 Company snapshot
9.6.3 Operating business segments
9.6.4 Product portfolio
9.6.5 Business performance
9.6.6 Key strategic moves and developments
9.7 Novartis
9.7.1 Company overview
9.7.2 Company snapshot
9.7.3 Operating business segments
9.7.4 Product portfolio
9.7.5 Business performance
9.7.6 Key strategic moves and developments
9.8 Lupin Pharmaceuticals, Inc.
9.8.1 Company overview
9.8.2 Company snapshot
9.8.3 Operating business segments
9.8.4 Product portfolio
9.8.5 Business performance
9.8.6 Key strategic moves and developments
9.9 Sun Pharmaceutical Industries, Inc.
9.9.1 Company overview
9.9.2 Company snapshot
9.9.3 Operating business segments
9.9.4 Product portfolio
9.9.5 Business performance
9.9.6 Key strategic moves and developments
9.10 Teva Pharmaceutical Industries Ltd.
9.10.1 Company overview
9.10.2 Company snapshot
9.10.3 Operating business segments
9.10.4 Product portfolio
9.10.5 Business performance
9.10.6 Key strategic moves and developments

Executive Summary

According to this report, titled, 'Pulmonary Arterial Hypertension Treatment Market,' The pulmonary arterial hypertension treatment market was valued at $7,177.81 million in 2021, and is projected to reach $11,968.60 million by 2031, growing at a CAGR of 5.2% from 2021 to 2031.

Pulmonary arterial hypertension (PAH) is a rare, progressive condition defined by chronically high blood pressure (hypertension) in the pulmonary arteries of the lungs. Blood from the right side of the heart travels through the lungs in the pulmonary arteries. Pulmonary arterial hypertension (PAH), or elevated left atrial pressure, which puts pressure on the pulmonary circulation, rises left atrial pressure, which then results in pulmonary venous hypertension. It is characterized by narrowed and blocked arteries and capillaries Symptoms associated with pulmonary artery hypertension including shortness of breath (dyspnea) especially during exercise, chest pain, fast pulse, and fatigue. Women between the ages of 30 and 60 are typically affected with pulmonary artery hypertension.

Major factors driving the growth of the pulmonary arterial hypertension treatment market include increase in focus on improving primary healthcare, increase in investment of government as well as non-government organization and increasing the accessibility of pulmonary arterial hypertension treatment products by making them available at affordable rates at government institutions. In addition, rise in rates of pulmonary arterial hypertension and advancements in technology and drug development, product launches, and initiatives by major organizations drive the growth of the market. For instance, in February and May 2019, Teva Pharmaceutical Industries Ltd. announced the two-product launch such as ALYQ product, is a phosphodiesterase 5 (PDE5) inhibitor and Ambiental is an endothelin receptor antagonist used to improve exercise activity of those patients with pulmonary artery hypertension. Moreover, increase in geriatric population and surge in number of HIV population further boost the market growth. For instance, American Journal of Managed Care (AJMC), a journal of clinical updates has published data in 2021, has estimated that in the U.S. and Europe, there are 15 to 50 cases of pulmonary artery hypertension per million people. About, 52.6% of all instances of pulmonary artery hypertension are idiopathic, hereditary, and anorexigenic-induced. Typically, women between the ages of 30 and 60 years are affected with pulmonary artery hypertension. However, the side effects associated with drug based pulmonary arterial hypertension is the factors which is anticipated to impede market expansion. Moreover, the market also offers growth opportunities to the key players in the market. As the development of new products to treat pulmonary arterial hypertension, there is an estimated a rise in demand for the pulmonary arterial hypertension treatment products during the forecast period.

The global pulmonary arterial hypertension treatment market is segmented on the basis of drug type, type, route of administration and region. As per drug type, the market is categorized into endothelin receptor antagonists (ERAs), PDE-5 inhibitors, prostacyclin, and prostacyclin analogs and sGC stimulators. On the basis of type, it is bifurcated into branded and generic. The branded segment is further classified into retail pharmacy, hospital pharmacy and online pharmacy. The generic segment is further classified into retail pharmacy, hospital pharmacy and online pharmacy. On the basis of route of administration, it is segmented into oral, intravenous/ subcutaneous, and inhalational. Region wise, it is analyzed across North America (the U.S., Canada, and Mexico), Europe (the UK, Germany, France, Italy, Spain, and rest of Europe), Asia-Pacific (China, India, Japan, Australia, South Korea and Rest of Asia-Pacific), and LAMEA (Brazil, Saudi Arabia, South Africa, and Rest of LAMEA).

The key players profiled in the study includes the Bayer AG, GlaxoSmithKline Plc, Gilead Sciences, Inc., Johnson & Johnson, Lupin Pharmaceuticals, Inc., Sandoz Inc. (Novartis), Sun Pharmaceutical Industries, Ltd., Teva Pharmaceutical Industries Ltd., United Therapeutics Corporation and Viatris Inc. The players in the market have been actively engaged in the adoption strategy such as product approval, acquisition, product launch and collaboration to remain competitive and gain advantage over the competitors in the market. For instance, in September 2020, the Janssen Pharmaceutical Companies of Johnson & Johnson has announced the submission of product application to FDA for the use of UPTRAVI product intravenously to cure the patient with pulmonary artery hypertension. In addition, in may 2021, Novartis has announced the use of Treprostinil Injection will be used by to treat pulmonary artery hypertension in patients. It is a medical treatment option that improves quality of life for patients and can be administered subcutaneously.

Key Market Insights

By drug type, the endothelin receptor antagonist segment was the highest revenue contributor to the market with a CAGR of 5.2% during the forecast period and is estimated to reach $3,558.19 million by 2031.

Based on type, the diagnosis segment dominates the market in 2021, and is expected to continue this trend during the forecast period.

Based on route of administration, the oral segment dominates the market in 2021, and is expected to continue this trend during the forecast period.

Based on region, North America garnered the largest revenue share in 2021, whereas Asia-Pacific is anticipated to grow at the highest CAGR of 7.2% during the forecast period

Companies Mentioned

• United Therapeutics Corporation
• Bayer AG
• Gilead Sciences, Inc.
• Johnson & Johnson
• Viatris Inc.
• GlaxoSmithKline
• Novartis
• Lupin Pharmaceuticals, Inc.
• Sun Pharmaceutical Industries, Inc.
• Teva Pharmaceutical Industries Ltd.

Methodology

The analyst offers exhaustive research and analysis based on a wide variety of factual inputs, which largely include interviews with industry participants, reliable statistics, and regional intelligence. The in-house industry experts play an instrumental role in designing analytic tools and models, tailored to the requirements of a particular industry segment. The primary research efforts include reaching out participants through mail, tele-conversations, referrals, professional networks, and face-to-face interactions.

They are also in professional corporate relations with various companies that allow them greater flexibility for reaching out to industry participants and commentators for interviews and discussions.

They also refer to a broad array of industry sources for their secondary research, which typically include; however, not limited to:

• Company SEC filings, annual reports, company websites, broker & financial reports, and investor presentations for competitive scenario and shape of the industry
• Scientific and technical writings for product information and related preemptions
• Regional government and statistical databases for macro analysis
• Authentic news articles and other related releases for market evaluation
• Internal and external proprietary databases, key market indicators, and relevant press releases for market estimates and forecast

Furthermore, the accuracy of the data will be analyzed and validated by conducting additional primaries with various industry experts and KOLs. They also provide robust post-sales support to clients.